GENECENTRIX INC.

  • Home

  • HistoReceptomics Platform

    • FAQ
    • Case Study
  • About Us

    • Our Team
    • Publications
  • Attrition Zero Blog

    • Contact Us
  • Contact GeneCentrix

  • More

    Use tab to navigate through the menu items.

    THE GENE

    EXPRESS

    Recent News

    Relief belief

    Relief belief

    Sick factor

    Sick factor

    Fast and spurious

    Fast and spurious

    Tags

    • Abeta
    • acute myeloid leukemia
    • ADME-Tox
    • adverse effects
    • AI
    • AIDS
    • allergies
    • Alzheimer's Disease
    • AML
    • ANA
    • anti-angiogenesis
    • anti-angiogenic
    • antibiotics
    • antidepressants
    • antiretroviral drugs
    • antiretroviral therapy
    • aortic rupture
    • ART
    • artificial intelligence
    • asthma
    • AstraZeneca
    • atrial fibrillation
    • attrition
    • attrition rate
    • autoimmune disease
    • autoimmunity
    • azithromycin
    • AZT
    • B-raf
    • big data
    • Biogen
    • biologics
    • biopharma
    • biotech
    • biotechnology
    • Braf
    • Brinavess
    • cancer
    • cancer clinical trials
    • cancer drugs
    • cancer treatment
    • cardiac cell contraction
    • Cas9
    • CCR5
    • Celgene
    • chemical database
    • chemical library
    • chemical ligands
    • chemical structure
    • chemical structures
    • cheminformatics
    • chinical trials
    • clinical hold
    • clinical testing
    • clinical trial
    • clinical trial Phase III study
    • clinical trials
    • clinicaltrials
    • clozapine
    • CNS
    • compound libraries
    • Correvio
    • COVID-19 drugs
    • COVID-19 mutation
    • COVID-19 Treatments
    • COVID-19 vaccine
    • CRISPR
    • CRISPR-Cas
    • curcumin
    • deep learning
    • DESCOVY
    • Diiachi Saykyo
    • DNA
    • DNASE1L3
    • drug
    Skip it

    Skip it

    Imagine you had a drug that dramatically improved the symptoms or signs of a disease in 70% of the patients who take it, but carried the...
    Meh-dicine

    Meh-dicine

    The holy grail of the pharma industry is FDA approval, but the final clue may be positive top-line (Phase III) results. However, it is...
    Dr. Knowlittle

    Dr. Knowlittle

    This one comes out of the past, but it is about a fear as old as time . . . or at least as old as Merck, namely that testing in animals...
    Clot twist

    Clot twist

    Just when you thought you were out, they pull you back in. We in the business obsess over the “valley of death” and the drug development...
    It's been a hard day's development

    It's been a hard day's development

    Pharma small molecule discovery has continued its longtime inexorable decline noted some time ago in this paper. There is little doubt...
    Prediction looks to the future

    Prediction looks to the future

    It’s long been known that better early prediction of drug-like compound properties overcomes costly drug attrition later. But prediction...
    Reading cancer's résumé

    Reading cancer's résumé

    Thinking about battling cancer without understanding its tissue of origin would be like hiring someone without knowing about their...
    No holds–barred!

    No holds–barred!

    Clinical holds are lost battles in the war against drug attrition. The process of drug development critically revolves around the FDA’s...
    Thymus up: the hidden powers of HCAC7

    Thymus up: the hidden powers of HCAC7

    Some autoimmune diseases, like lupus, affect multiple tissues, but some, like inflammatory bowel disease, affect only specific types. A...
    Could GeneCentrix's Historeceptomics Profiler have saved millions for Roche and PTC Therapeutics

    Could GeneCentrix's Historeceptomics Profiler have saved millions for Roche and PTC Therapeutics

    Roche and PTC’s Spinal Muscular Atrophy clinical drug trials were waylaid by an unexpected tissue specific effect. After the trial had...
    1
    2
     

    Get Attrition Zero, all the latest drug development news, delivered to your inbox.

    Follow us:

    ©2018-2020 GeneCentrix, Inc.                                                                            FCOI Policy